{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:34:17Z","timestamp":1773927257776,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Liaoning Provincial Department of Education","award":["LJ112410163013"],"award-info":[{"award-number":["LJ112410163013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15579-1","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:22:09Z","timestamp":1768962129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of anti-VEGF\/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: a network meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Min","family":"Duan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuojing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Zong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"02","key":"15579_CR1","first-page":"73","volume":"14","author":"Z Xu","year":"2025","unstructured":"Chinese Urological Association, Renal Carcinoma Research Collaborative Group, Xu Z, Zhisong H, Jian H, Xin M, et al. Chinese expert consensus on immunotherapy for renal cell carcinoma. J Minim Invasive Urol. 2025;14(02):73\u201383.","journal-title":"J Minim Invasive Urol"},{"issue":"3","key":"15579_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ucl.2020.04.005","volume":"47","author":"SVL Vig","year":"2020","unstructured":"Vig SVL, Zan E, Kang SK. Imaging for metastatic renal cell carcinoma. Urologic Clin North Am. 2020;47(3):281\u201391.","journal-title":"Urologic Clin North Am"},{"issue":"3","key":"15579_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"8","key":"15579_CR4","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.3390\/curroncol31080351","volume":"31","author":"CL Park","year":"2024","unstructured":"Park CL, Moria FA, Ghosh S, Wood L, Bjarnason GA, Bhindi B, et al. Impact of timing of immunotherapy and cytoreductive nephrectomy in metastatic renal cell carcinoma: Real-World data on survival outcomes from the CKCis database. Curr Oncol. 2024;31(8):4704\u201312.","journal-title":"Curr Oncol"},{"issue":"2","key":"15579_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.eururo.2024.10.019","volume":"87","author":"R Barragan-Carrillo","year":"2025","unstructured":"Barragan-Carrillo R, Saad E, Saliby R-M, Sun M, Albiges L, Bex A, et al. First and Second-line treatments in metastatic renal cell carcinoma. Eur Urol. 2025;87(2):143\u201354.","journal-title":"Eur Urol"},{"issue":"3","key":"15579_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.eururo.2018.03.036","volume":"74","author":"CJD Wallis","year":"2018","unstructured":"Wallis CJD, Klaassen Z, Bhindi B, Ye XY, Chandrasekar T, Farrell AM, et al. First-line systemic therapy for metastatic renal cell carcinoma: A systematic review and network Meta-analysis. Eur Urol. 2018;74(3):309\u201321.","journal-title":"Eur Urol"},{"key":"15579_CR7","doi-asserted-by":"publisher","first-page":"689132","DOI":"10.3389\/fimmu.2021.689132","volume":"12","author":"S Ren","year":"2021","unstructured":"Ren S, Xiong X, You H, Shen J, Zhou P. The combination of immune checkpoint Blockade and angiogenesis inhibitors in the treatment of advanced Non-Small cell lung cancer. Front Immunol. 2021;12:689132.","journal-title":"Front Immunol"},{"key":"15579_CR8","doi-asserted-by":"publisher","first-page":"k3529","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ (Clinical Res ed). 2018;362:k3529.","journal-title":"BMJ (Clinical Res ed)"},{"key":"15579_CR9","doi-asserted-by":"crossref","unstructured":"Mahaki H, Nobari S, Tanzadehpanah H, Babaeizad A, Kazemzadeh G, Mehrabzadeh M, et al. Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: therapeutic strategies and insights. Biomed Pharmacother. 2025;186:118023.","DOI":"10.1016\/j.biopha.2025.118023"},{"issue":"11","key":"15579_CR10","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.23.01569","volume":"42","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, et al. Lenvatinib plus pembrolizumab versus Sunitinib in First-Line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol. 2024;42(11):1222\u20138.","journal-title":"J Clin Oncol"},{"key":"15579_CR11","doi-asserted-by":"crossref","unstructured":"Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, et al. Nivolumab plus Cabozantinib versus Sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised checkmate 9ER trial. ESMO Open. 2024;9(5):102994.","DOI":"10.1016\/j.esmoop.2024.102994"},{"issue":"12","key":"15579_CR12","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Souli\u00e8res D, Waddell T, Stus V, Gafanov R, et al. Pembrolizumab plus axitinib versus Sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563\u201373.","journal-title":"Lancet Oncol"},{"key":"15579_CR13","unstructured":"Qihao W, Jianjun Y, Xinyang L, Zeyu C, Lei Z, Qiang W, et al. First-Line Systemic Treatments in NccRCC: A Systematic Review and Network Meta-Analysis of RCTs. null 2025."},{"issue":"2","key":"15579_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/COC.0000000000001150","volume":"48","author":"A Jamil","year":"2025","unstructured":"Jamil A, Qureshi Z, Siddique R, Altaf F, Akram H. Efficacy and safety of lenvatinib in combination with other tyrosine kinase inhibitors for metastatic renal cell carcinoma. Am J Clin Oncol. 2025;48(2):92\u2013105.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"15579_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","volume":"35","author":"XQ Yan","year":"2024","unstructured":"Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, et al. Toripalimab plus axitinib versus Sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol. 2024;35(2):190\u20139.","journal-title":"Ann Oncol"},{"issue":"6","key":"15579_CR16","doi-asserted-by":"publisher","first-page":"7051","DOI":"10.1002\/cam4.5504","volume":"12","author":"R Xie","year":"2022","unstructured":"Xie R, Wu J, Shang B, Bi X, Jiang W, Cao C, et al. Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta-analysis of safety. Cancer Med. 2022;12(6):7051\u201364.","journal-title":"Cancer Med"},{"key":"15579_CR17","doi-asserted-by":"crossref","unstructured":"Chen X, Xu Z, Wu C, Xie L, Wang P, Liu X. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis. Front Immunol. 2024;8:15:1255577.","DOI":"10.3389\/fimmu.2024.1255577"},{"key":"15579_CR18","doi-asserted-by":"crossref","unstructured":"Krawczyk K, \u015aladowska K, Holko P, Kawalec P. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. Front Pharmacol. 2023;7:14:1223929.","DOI":"10.3389\/fphar.2023.1223929"},{"key":"15579_CR19","doi-asserted-by":"crossref","unstructured":"Robert JM, Eric J, Neeraj A, Ajjai A, Michael JB, Kathryn EB, et al. Kidney Cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network: JNCCN. 2022;20(1):71\u201390.","DOI":"10.6004\/jnccn.2022.0001"},{"key":"15579_CR20","doi-asserted-by":"crossref","unstructured":"Axel B, Yasmin Abu G, Laurence A, Stephanie EB, Riccardo C, Umberto C, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update. European urology. 2025;87(6):683\u201396.","DOI":"10.1016\/j.eururo.2025.02.020"},{"key":"15579_CR21","unstructured":"Chinese expert consensus on the systemic. treatment of advanced clear cell renal cell carcinoma (2024 edition). Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2024;46(9):844\u201354."},{"key":"15579_CR22","unstructured":"Matthew JP, Joanne EM, Patrick MB, Isabelle B, Tammy H, Cynthia DM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed)\u00a0. 2021;18(3):e1003583."},{"key":"15579_CR23","doi-asserted-by":"crossref","unstructured":"Julian PTH, Doug A, Peter CG, Peter J, David M, Andrew DO, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ (Clinical Res ed). 2011;18:343:d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"15579_CR24","doi-asserted-by":"publisher","first-page":"111985","DOI":"10.1016\/j.jclinepi.2025.111985","volume":"188","author":"AA Veroniki","year":"2025","unstructured":"Veroniki AA, Tricco AC, Rangira D, McKenzie JE, Li T, Straus SE, et al. Updating the PRISMA reporting guideline for network meta-analysis: a scoping review. J Clin Epidemiol. 2025;188:111985.","journal-title":"J Clin Epidemiol"},{"key":"15579_CR25","unstructured":"David JS, Nicola B, Bradley PC, van der Angelika L. Bayesian measures of model complexity and fit. J Royal Stat Soc Ser B-Statistical Methodol. 2002."},{"key":"15579_CR26","unstructured":"David S, Nicola B, Bradley PC. Angelika Van der L: bayesian measures of model complexity and fit. Qual Eng. 2003."},{"key":"15579_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jclinepi.2016.02.016","volume":"76","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Straus SE, Fyraridis A, Tricco AC. The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes. J Clin Epidemiol. 2016;76:193\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"15579_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/17425255.2016.1120287","volume":"12","author":"C Ciccarese","year":"2016","unstructured":"Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C, et al. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(1):57\u201375.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"15579_CR29","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","volume":"14","author":"BI Rini","year":"2013","unstructured":"Rini BI, Melichar B, Ueda T, Gr\u00fcnwald V, Fishman MN, Arranz JA, et al. Axitinib with or without dose Titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013;14(12):1233\u201342.","journal-title":"Lancet Oncol"},{"issue":"5","key":"15579_CR30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.clgc.2023.06.012","volume":"21","author":"BC Carthon","year":"2023","unstructured":"Carthon BC, Kim SE, McDermott DF, Dutcher JP, Puligandla M, Manola J, et al. Results from a randomized phase II trial of Sunitinib and gemcitabine or Sunitinib in advanced renal cell carcinoma with sarcomatoid features: ECOG-ACRIN E1808. Clin Genitourin Cancer. 2023;21(5):546\u201354.","journal-title":"Clin Genitourin Cancer"},{"issue":"30","key":"15579_CR31","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","volume":"31","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, et al. Tivozanib versus Sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791\u20139.","journal-title":"J Clin Oncol"},{"issue":"10189","key":"15579_CR32","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. Atezolizumab plus bevacizumab versus Sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404\u201315.","journal-title":"Lancet"},{"key":"15579_CR33","doi-asserted-by":"crossref","unstructured":"Haanen JBAG, Larkin J, Choueiri TK, Albiges L, Rini BI, Atkins MB, et al. Extended follow-up from JAVELIN renal 101: subgroup analysis of avelumab plus axitinib versus Sunitinib by the international metastatic renal cell carcinoma database consortium risk group in patients with advanced renal cell carcinoma. ESMO Open. 2023;8(3):101210.","DOI":"10.1016\/j.esmoop.2023.101210"},{"issue":"1","key":"15579_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/bju.15058","volume":"126","author":"SK Pal","year":"2020","unstructured":"Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, et al. Patient-reported outcomes in a phase 2 study comparing Atezolizumab alone or with bevacizumab vs Sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int. 2020;126(1):73\u201382.","journal-title":"BJU Int"},{"issue":"33","key":"15579_CR35","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.24.00767","volume":"42","author":"P Barata","year":"2024","unstructured":"Barata P, Tangen C, Plets M, Thompson IM, Narayan V, George DJ, et al. Final overall survival analysis of S1500: A Randomized, phase II study comparing Sunitinib with Cabozantinib, Crizotinib, and Savolitinib in advanced papillary renal cell carcinoma. J Clin Oncol. 2024;42(33):3911\u20136.","journal-title":"J Clin Oncol"},{"key":"15579_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","volume":"94","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, et al. Cabozantinib versus Sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115\u201325.","journal-title":"Eur J Cancer"},{"key":"15579_CR37","doi-asserted-by":"crossref","unstructured":"Lee JL, Kim MK, Inkeun P, Ahn JH, Daniel L, Hun-Mo R, et al. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial. Annals Oncology: Official J Eur Soc Med Oncol. 2015;26(11):2300\u20135.","DOI":"10.1093\/annonc\/mdv357"},{"issue":"12","key":"15579_CR38","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","volume":"30","author":"RJ Motzer","year":"2012","unstructured":"Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, et al. Randomized phase II trial of Sunitinib on an intermittent versus continuous dosing schedule as First-Line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30(12):1371\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15579_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clgc.2016.05.008","volume":"15","author":"TE Hutson","year":"2017","unstructured":"Hutson TE, Al-Shukri S, Stus VP, Lipatov ON, Shparyk Y, Bair AH, et al. Axitinib versus Sorafenib in First-Line metastatic renal cell carcinoma: overall survival from a randomized phase III trial. Clin Genitourin Cancer. 2017;15(1):72\u20136.","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"15579_CR40","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus Sunitinib in metastatic Renal-Cell carcinoma. N Engl J Med. 2013;369(8):722\u201331.","journal-title":"N Engl J Med"},{"key":"15579_CR41","doi-asserted-by":"publisher","unstructured":"Andrew J, Matthew TC, Pavlos M, Eric J, Andrew WH, Jianjun G, et al. CABOSUN II: results from a phase 2, open-label, multi-center randomized study of Cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC). J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.4597.","DOI":"10.1200\/jco.2023.41.16_suppl.4597."},{"issue":"6","key":"15579_CR42","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061\u20138.","journal-title":"J Clin Oncol"},{"issue":"9","key":"15579_CR43","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S1470-2045(25)00343-2","volume":"26","author":"A Zhou","year":"2025","unstructured":"Zhou A, Shen P, Li J, Qu W, Wang Z, Ren X, et al. First-line Benmelstobart plus anlotinib versus Sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26(9):1145\u201357.","journal-title":"Lancet Oncol"},{"issue":"8","key":"15579_CR44","doi-asserted-by":"publisher","first-page":"e702","DOI":"10.1634\/theoncologist.2018-0839","volume":"24","author":"A-P Zhou","year":"2019","unstructured":"Zhou A-P, Bai Y, Song Y, Luo H, Ren X-B, Wang X, et al. Anlotinib versus Sunitinib as First-Line treatment for metastatic renal cell carcinoma: A randomized phase II clinical trial. Oncologist. 2019;24(8):e702\u20138.","journal-title":"Oncologist"},{"key":"15579_CR45","unstructured":"WM BETE, C S, S O S, C MSSN. C, E S, AA D: Sorafenib in advanced clear-cell renal-cell carcinoma. 2007; 356(2):125\u201334."},{"issue":"4","key":"15579_CR46","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/j.clgc.2020.01.001","volume":"18","author":"Y Tomita","year":"2020","unstructured":"Tomita Y, Naito S, Sassa N, Takahashi A, Kondo T, Koie T, et al. Sunitinib versus Sorafenib as initial targeted therapy for mCC-RCC with Favorable\/Intermediate risk: multicenter randomized trial CROSS-J-RCC. Clin Genitourin Cancer. 2020;18(4):e374\u201385.","journal-title":"Clin Genitourin Cancer"},{"key":"15579_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2018.11.001","volume":"107","author":"M Retz","year":"2019","unstructured":"Retz M, Bedke J, B\u00f6gemann M, Grimm M-O, Zimmermann U, M\u00fcller L, et al. SWITCH II: phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33\/11). Eur J Cancer. 2019;107:37\u201345.","journal-title":"Eur J Cancer"},{"issue":"5","key":"15579_CR48","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.eururo.2015.04.017","volume":"68","author":"C Eichelberg","year":"2015","unstructured":"Eichelberg C, Vervenne WL, De Santis M, von Fischer L, Goebell PJ, Lerchenm\u00fcller C, et al. SWITCH: A Randomised, Sequential, Open-label study to evaluate the efficacy and safety of Sorafenib-sunitinib versus Sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur Urol. 2015;68(5):837\u201347.","journal-title":"Eur Urol"},{"key":"15579_CR49","unstructured":"van Gert V, Guobing L, Bert de B, Hans LH, Ades AE, Nicky JW. Automating network meta-analysis. Res Synthesis Methods 2012."},{"issue":"1","key":"15579_CR50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","volume":"6","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Reviews. 2017;6(1):79.","journal-title":"Syst Reviews"},{"key":"15579_CR51","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","volume":"120","author":"R Roskoski Jr","year":"2017","unstructured":"Roskoski R Jr. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacol Res. 2017;120:116\u201332.","journal-title":"Pharmacol Res"},{"issue":"11","key":"15579_CR52","doi-asserted-by":"publisher","first-page":"8142","DOI":"10.21037\/tcr-2025-1859","volume":"14","author":"K Iinuma","year":"2025","unstructured":"Iinuma K, Tomioka M, Taniguchi T, Kawase K, Tobisawa Y, Nakane K, et al. Combination immunotherapy in Japanese patients with advanced renal cell carcinoma: bridging gaps between clinical trials, real-world evidence, and the potential value of adverse events-a narrative review. Translational Cancer Res. 2025;14(11):8142\u201353.","journal-title":"Translational Cancer Res"},{"key":"15579_CR53","doi-asserted-by":"publisher","first-page":"S1263","DOI":"10.1016\/j.annonc.2024.08.2319","volume":"35","author":"X Sheng","year":"2024","unstructured":"Sheng X, Shen P, Qu W, Wang Z, Li Y, Ren X, et al. LBA76 anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus Sunitinib in first-line treatment of advanced renal cell carcinoma (RCC): A randomized, open-label, phase III study (ETER100). Ann Oncol. 2024;35:S1263\u20134.","journal-title":"Ann Oncol"},{"issue":"1","key":"15579_CR54","doi-asserted-by":"publisher","first-page":"43676","DOI":"10.1038\/s41598-025-27578-6","volume":"15","author":"T Kato","year":"2025","unstructured":"Kato T, Nakai Y, Sato M, Takao T, Iwanishi T, Toyoda S, et al. Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study. Sci Rep. 2025;15(1):43676.","journal-title":"Sci Rep"},{"issue":"6","key":"15579_CR55","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.bja.2023.02.041","volume":"130","author":"B Doleman","year":"2023","unstructured":"Doleman B, Mathiesen O, Sutton AJ, Cooper NJ, Lund JN, Williams JP. Non-opioid analgesics for the prevention of chronic postsurgical pain: a systematic review and network meta-analysis. Br J Anaesth. 2023;130(6):719\u201328.","journal-title":"Br J Anaesth"},{"key":"15579_CR56","doi-asserted-by":"crossref","unstructured":"Msaouel P, Yu K, Yuan Y, Chen J, Yan X, Karki M, et al. Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial. Nat Commun. 2025;16(1):578.","DOI":"10.1038\/s41467-024-55642-8"},{"key":"15579_CR57","doi-asserted-by":"crossref","unstructured":"Barata P, Gulati S, Elliott A, Hammers HJ, Burgess E, Gartrell BA, et al. Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles. J Clin Invest. 2024;134(11):e178915.","DOI":"10.1172\/JCI178915"},{"key":"15579_CR58","doi-asserted-by":"crossref","unstructured":"Pashai Fakhri M, Serth J, Br\u00e4sen JH, Ivanyi P, Kuczyk MA, Tezval H. Chromophobe renal cell carcinoma \u2013 a rare kidney cancer with limited therapy options: a narrative review. BMC Urol. 2025;25(1):147.","DOI":"10.1186\/s12894-025-01816-5"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15579-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15579-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15579-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:13:24Z","timestamp":1773915204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15579-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15579"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15579-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7826015\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"369"}}